Hypothesis/Commentary

What Can We Learn about Disease Etiology from Case-Case Analyses? Lessons from Breast Cancer

Maria Elena Martinez1,2, Giovanna I. Cruz1,2, Abenaa M. Brewster3, Melissa L. Bondy3, and Patricia A. Thompson1,2

Introduction

In this commentary, we discuss the challenges and opportunities for epidemiologic studies in evaluating breast cancer as a set of discrete diseases. We show examples of the strengths of the case-only design in assessing the relative correlation of established risk factors and the different cancer subtypes. We argue for the use of the case-only study design as an important initial step in understanding the extent of etiologic heterogeneity between tumor subtypes.

Breast Tumor Heterogeneity and Etiology

Unlike cardiovascular disease, where distinct disease subtypes and etiologic factors are recognized (e.g., ischemic versus hemorrhagic stroke), cancer is in its infancy with regard to an understanding of distinct causal pathways. However, breast cancer is perhaps in an adolescent stage, given the important recent advances in the genomic characterization of breast tumors. These advances have shown that breast cancers segregate reproducibly into discrete groups that differ in their clinical behaviors (1-3). The molecular subtypes identified by gene expression profiles align, expectedly, in the first order of clustering algorithms along the estrogen receptor (ER) status of the tumor (1). Motivation for second-order classification and characterization stems from an important and over-arching interest to understand the clinical significance of second- and third-order heterogeneities in terms of patient outcomes and drug discovery efforts. This latter effort has led to an evolving set of classifications of breast cancers that encompass at least four clinically relevant and highly reproducible subclasses: luminal A, luminal B, ERBB2-amplified (HER2+), and basaloid type tumors. Thus, from a patient outcome perspective, it is clear that second-order and, perhaps, third-order heterogeneities exist among breast tumors that are clinically meaningful. However, for epidemiology, where the interest is in the etiologic perspective, it is unclear how much this heterogeneity results from clonal expansion and evolution of a common progenitor cell or is simply a consequence of carcinogenesis in separate cell lineages for which a distinct constellation of causal factors exist.

The view of breast cancer, not as a set of stochastic molecular events but as a finite set of separate tumorigenesis events, is not entirely new to genomics. In 1995, Potter et al. (4) provided some of the earliest evidence supporting etiologic heterogeneity among breast cancers showing an inverse association between parity and ER/progesterone receptor (PR)–positive tumors that was not present for ER/PR–negative tumors. A decade later, the Nurses’ Health Study reported that parity and early age of first pregnancy were inversely associated with ER+/PR+ tumors, but not with ER−/PR− tumors (5); these data were replicated in a later meta-analysis (6). More recent studies support the presence of distinct reproductive and genetic risk factor profiles among the tumor subtypes that largely divide on hormone receptor status (7-9). Additional evidence in support of distinct disease subtypes derives from studies of tumors arising in BRCA1 and BRCA2 germline mutation carriers. BRCA1 carriers develop basaloid tumors (10, 11), for which early first pregnancy acts as a risk factor (12). In contrast, BRCA2 carriers develop luminal tumors, for which early first pregnancy is protective (12-14). These opposing effects of age of first pregnancy and tumor type–specific risk in the BRCA cases provide some of the strongest evidence that breast cancer subtypes can and likely do arise through distinct causal pathways.

Studying the Epidemiology of Breast Tumor Subtypes

Recent developments in breast tumor classification based on molecular characteristics pose significant methodologic challenges for conventional epidemiologic studies of breast cancer etiology and risk assessment. First, there is the lack of consensus on disease classification and subtype definitions. Ignoring the lack of consensus, routinely reported tumor markers such as ER and PR status are insufficient to categorize cases into the newly described molecular-based subtypes. Therefore, tissue collection from cases is necessary to obtain additional gene and protein measures to derive the classification. However, tissue collection presents its own set of challenges for population-based epidemiologic studies including costs, issues of ownership and consent, and...
increasingly smaller tumors and biopsy-based sampling. Second, depending on the number of subtypes and their prevalence, traditional cohort and case-control studies face problems related to statistical power; the result is study findings that are inconsistent, imprecise, and ultimately, uninformative. A few recent studies have attempted to begin to address these challenges by pooling data from numerous studies and stratifying on ER and PR status and other clinical features (15, 16). These pooled studies have mainly focused on genetic susceptibility loci as the main risk factors of interest. Integration of epidemiologic exposure variables has proved more challenging for the pooling approach because of nonstandard collection of information on exposures. Additional challenges specific to case-control studies include appropriate control selection and low response rates among controls. This latter issue is especially true for studies of racial/ethnic minorities and other disadvantaged populations, where we now have evidence of different disease patterns for the breast cancer subsets (9). In these populations, it is also essential to consider matching on race/ethnicity or to use family-based studies to minimize population stratification.

**Case-Case Analysis of Breast Cancer Etiology**

In a case-only study design, information is obtained only from cases of a particular disease (i.e., breast cancer), with no information obtained from individuals without the disease. In genetic epidemiology, the case-only design has been used to study the effects of the interaction between environmental factors and genetic variants (17). Assuming independence between the genetic and environmental factor, a differential association with the environmental risk factor of interest by genotype is interpreted as supportive of etiologic heterogeneity (17, 18). In addition, as early as 1984, Prentice et al. (19) introduced the concept of using a case-only study for identifying disease risk factors. More recently, case-case analyses have been used as an exploratory tool to assess etiologic heterogeneity in the context of breast cancer; here, the most common breast tumor subtype (luminal A) is used as the reference group against which the other subtypes are compared for their odds of having a given exposure. The rationale is that a difference in the relationship between the exposure supports, but does not necessarily prove, the hypothesis of distinct effects on the discrete disease subsets.

**Comparison of case-case and case-control analyses**

To illustrate our argument for the use of the case-only analysis, we use data from two published studies that have explored breast cancer etiologic heterogeneity. The first is from the Carolina Breast Cancer Study (CBCS), which is a population-based case-control study of African-American and white women in North Carolina (9). The second is a pooled analysis of data from five individual studies used to assess genetic susceptibility loci as risk factors for breast cancer (16).

The CBCS included 1,424 cases of invasive and in situ breast cancer and 2,022 disease-free controls. The study examined associations for a variety of traditional breast cancer risk factors in relation to five immunohistochemical tumor marker defined subtypes. This study setting provided a unique opportunity to conduct a parallel comparison of the results from a case-case and a case-control analysis for a variety of reproductive and lifestyle factors. When assessing age at menarche (<13 versus ≥13 years), the case-case odds ratio (OR) was 1.3 for basal-like cases (i.e., tumors that are ER−, PR−, HER2−, HER1+, and/or CK5/6+) compared with luminal A cases (i.e., tumors that are ER+ and/or PR+ and HER2−). Here, the case-case OR represents the ratio of the ORs for the different subtypes and shows that cases with basal-like tumors are more likely to report an earlier age at menarche when compared with cases with luminal A-like tumors. In the case-control analysis, where disease-free controls are used as the comparison group, cases with luminal A tumors had a 1.1 odds of reporting an earlier age of menarche, whereas the corresponding odds for cases with basal-like tumors was 1.4. Based on the difference in magnitude and direction of the association in the case-control setting (luminal A OR 1.1 versus basal-like OR 1.4), we interpret this relationship to mean that cases with basal-like tumors are more likely to have an earlier age of menarche than cases with luminal A tumors. These findings are consistent with the interpretation from the case-only analysis. Perhaps a more interesting comparison between the two designs is related to parity, where there is prior evidence for a differential effect of parity by tumor subtype (5, 6, 20). The case-control analysis shows that compared with nulliparous controls, cases with luminal A tumors had a lower odds of having 1, 2, or 3 or more births (OR of 0.7 for all three categories). Conversely, cases with basal-like tumors had an increased odds of reporting higher parity compared with nulliparous controls. Furthermore, for cases with basal-like tumors, the association strengthened with additional births, with ORs of 1.7, 1.8, and 1.9 for 1, 2, and 3 or more births, respectively. In the case-case analysis, basal-like tumors were more likely to occur among parous women compared with luminal A tumors (ORs of 1.6 for 1-2 children and 1.7 for 3+ children). In addition to these examples, concordant results were shown for breastfeeding, waist-to-hip ratio, and other factors between the case-case and case-control analyses in the CBCS. Thus, although these empirical results could be subject to bias, the comparisons illustrate that the information gained for the association between established breast cancer risk factors and tumor subtype is generally comparable using the two study design approaches.

This conclusion is further strengthened by recent analyses of the genetic studies in breast cancer. For example, as in the case of the CBCS, Stacey et al. (16) conducted case-control and case-case analyses of genetic variants
on chromosome 5p12 in relation to breast cancer risk. Unlike the CBCS, this study did not have data on the intrinsic tumor subtypes; therefore, susceptibility was only assessed by ER status. In the case-control analysis, the OR for the presence of the T allele in the single nucleotide polymorphism rs4415084 and breast cancer risk was 1.16; however, stratification by ER status showed no association for ER-negative tumors versus controls (OR, 0.98) and a positive association for ER-positive tumors (OR, 1.23). The case-case OR for ER-positive versus ER-negative tumors was 1.25, which is merely an estimate of the ratio of the ORs (1.23/0.98). In this scenario, both ORs are essentially identical, given that no association is apparent between the genetic locus and ER-negative tumors. It is also important to point out that this study included a large population (5,028 cases and 32,090 controls), providing adequate statistical power to uncover this degree of heterogeneity.

**Interpretation of Case-Only ORs and Etiologic Heterogeneity**

In Fig. 1, we illustrate the findings of the case-control and case-case analyses of breast cancer in the presence and absence of etiologic heterogeneity. In the presence of heterogeneity (left), parity, for example, would be positively associated with ER− tumors and negatively associated with ER+ tumors (5, 6, 20). In this setting of etiologic heterogeneity, the case-control OR will reflect the differential direction of the effect, and the case-case OR, which is an estimate of the ratio of the case-control ORs for ER subtypes, will have a value greater than 1 when comparing ER− versus ER+ disease subtypes. For the absence of heterogeneity (right), we use the genetic locus on MAP2K1, which has been reported to be positively associated with risk of both ER+ and ER− tumor subtypes (21). In this case, the risk factor is positively associated with risk of both tumor subtypes; the case-control ORs will show a value greater than 1, whereas the case-case OR will be null or close to this value. In this scenario, the case-only study is interpreted as a failure in showing etiologic heterogeneity for this risk factor between the tumor subtypes.

Given the proposed disease heterogeneity observed in breast cancer, future large epidemiologic studies will be helpful in identifying etiologic heterogeneity for the established, traditional risk factors by disease subtype. However, it must be noted that our knowledge is still incomplete, given that to date, sample sizes for the less common tumor subtypes have been limited. Furthermore, as noted earlier, the precise, clinically significant tumor subtypes are still unknown, and this continues to be an active area of research. Although highly speculative, the presence of common chromosomal aberrations in basal-like, HER2, and luminal B type tumors that are distinct from those arising in luminal A type tumors has led to the suggestion that etiology may be limited to two distinct cancer progenitors, again largely splitting on the ER status (22). These studies highlight the need for further integration of molecular classifications to refine our definition of disease outcome in epidemiologic studies of breast cancer.

**Limitations of Case-Case Analyses**

In spite of its strengths, the case-only study design has obvious limitations. Importantly, a study that does not include a disease-free population does not provide a
traditional risk ratio and may not provide a valid estimate of the association between a risk factor and disease. The resulting OR can only be interpreted as the ratio of the odds of exposure for a given subtype (i.e., basal-like) in reference to another (i.e., luminal A). Thus, the case-only OR can never be interpreted as a measure of risk for the specific subtype. Furthermore, the magnitude of the association is not the magnitude of risk, but rather an indicator of the general direction of the correlation between risk factor and subtype. For example, in the BCBCS, the case-case OR for basal-like compared with luminal A tumors for women who reported having 3 or more children underestimates the true association, given that the corresponding case-control OR analysis shows a higher estimate of the effect (1.9 in the case-control analysis versus 1.7 in the case-only analysis). Arguably, the magnitude of the error in the estimate will depend on the association of the risk factor with the case group that is used for the comparison (i.e., luminal A or ER subtype). In the study by Stacey et al. (16) discussed above, the case-case and case-control ORs were essentially identical, given that the effect of the genetic locus was nearly entirely confined to ER-positive tumors.

Utility of the Case-Only Study Design for Studies of Breast Cancer

We propose that the case-only approach can be particularly useful to uncover the differences or similarities in association between a risk factor and a tumor subtype. This study design is an important and efficient initial step in defining risk factor profiles for each subtype and providing first-level evidence for etiologic heterogeneity. In fact, published studies that have incorporated tumor marker information, such as ER and PR status, have begun to uncover etiologic heterogeneity for several traditional breast cancer risk factors and disease subtypes as proof of principle of the value of this strategy and the need to consider the adverse effects of lumping all breast cancers into a single outcome (5, 8, 9, 20).

The problem of low sample size and statistical power to detect etiologic heterogeneity will apply to even reasonably large studies such as the BCBCS. For example, in the BCBS, whereas the prevalence of the basal-like tumors is ~16%, that for HER2+/ER− tumors is a modest 8%. As also noted earlier, it must be emphasized that the exact number of etiologically distinct breast tumor subtypes is currently unknown. Thus, case-only studies can be a useful tool for providing additional clues for collapsing groups on etiologic similarity to guide stratification and identify potential subtype-specific risk factors, as originally proposed by Prentice et al. (19).

We argue that to continue to move the breast cancer field forward in a rapid fashion integrating new knowledge on tumor heterogeneity, epidemiologic studies need to include tissue collection to integrate information on tumor markers beyond those that are traditionally available in population-based tumor registries. However, tissue collection can be problematic and poses a universal challenge to the field. One solution is to obtain tissue samples from cases in which relatively high retrieval rates are feasible, such as clinic-based samples. Recognizing the interpretation limitations of this approach for the general population, clinic-based sampling could be a valuable and unique strategy to investigate the etiologic correlates of tumor subtypes to advance our understanding of etiologic heterogeneity.

Conclusion

The case-only design is a useful tool in the process of building a risk factor profile by identifying correlations between risk factor and disease subtype. This utility can prove beneficial for all diseases where considerable heterogeneity is plausible. Arguably, results from case-case analyses must be interpreted with caution and validated in traditional case-control and cohort studies to assess risk and estimate the exact magnitude of the effect. If indeed the subtypes represent distinct disease types, knowledge gained from the case-only setting is likely to derive important information on tumor subtype-specific risk factors for tailoring and testing risk prediction models that could ultimately inform risk reduction strategies.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

The Avon Foundation, a supplement to the Arizona Cancer Center Core Grant from the National Cancer Institute (CA-023074-2953), a supplement to the M.D. Anderson Cancer Center Specialized Program of Research Excellence in Breast Cancer (P50 CA116199-02S1), and a grant from Susan G. Komen for the Cure (KG090934).

Received 07/14/2010; revised 08/19/2010; accepted 08/26/2010; published OnlineFirst 09/24/2010.

References

6. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and...


What Can We Learn about Disease Etiology from Case-Case Analyses? Lessons from Breast Cancer

María Elena Martínez, Giovanna I. Cruz, Abenaa M. Brewster, et al.


Updated version

Access the most recent version of this article at:
doi:10.1158/1055-9965.EPI-10-0742

Cited articles

This article cites 22 articles, 8 of which you can access for free at:
http://cebp.aacrjournals.org/content/19/11/2710.full#ref-list-1

Citing articles

This article has been cited by 2 HighWire-hosted articles. Access the articles at:
http://cebp.aacrjournals.org/content/19/11/2710.full#related-urls

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.